We are developing a cohort of individuals diagnosed with HIV at a late stage to better understand the clinical and social factors involved. This project, carried out in collaboration with Hospital del Mar, helps identify missed opportunities for earlier diagnosis and supports the development of new intervention strategies.

This study investigates whether baricitinib, a drug already approved for certain inflammatory diseases, can reduce HIV persistence in people whose virus is well controlled through antiretroviral treatment. It will also assess whether the drug affects cellular mechanisms that allow the viral reservoir to survive. The findings will help determine whether baricitinib can contribute to new combination strategies involving therapeutic vaccines and other immunotherapies aimed at achieving long-term HIV remission.

This initiative was created to support women living with HIV during menopause. It consists of a series of sessions that provide a holistic approach centred on the body and personal experience during this stage of life, recognising the body as a space of both experience and knowledge. The sessions are structured around the different stages of the climacteric period (premenopause, perimenopause, menopause and postmenopause), with content tailored to each phase.

Healthy Connections is an innovative project designed to improve the quality of life of people living with HIV. It aims to create a territorial ecosystem of health and community services that delivers more integrated, accessible and personalised care. Particular attention is given to vulnerable populations, including women, people over the age of 55 and migrants.

RIO is an international study in which the Foundation collaborates to evaluate a new strategy that could allow people living with HIV to maintain viral suppression without the need for continuous antiretroviral treatment. The project investigates the use of broadly neutralising antibodies (bNAbs), which can block multiple HIV variants and stimulate the immune response. The goal is to determine whether these antibodies can extend viral control after a supervised treatment interruption and identify which individuals may benefit most from these innovative approaches.

We study the impact of ageing in people living with HIV aged 50 and over, with a particular focus on frailty and comorbidities. We develop multidisciplinary interventions aimed at improving functional capacity and quality of life.